Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response
Vitiligo is an acquired depigmentation skin disease caused by immune-mediated death of melanocytes. The most common treatment for vitiligo is narrow band ultraviolet B phototherapy, which often is combined with topical therapies such as tacrolimus. However, patients’ responses to these treatments sh...
Main Authors: | Qianli Yang, Guohong Zhang, Mingwan Su, Gigi Leung, Harvey Lui, Pingyu Zhou, Yan Wu, Joshua Zhou, Jinhua Xu, Xuejun Zhang, Youwen Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.613031/full |
Similar Items
-
Comparison of Effectiveness of Narrow Band Ultraviolet B Therapy Combined with 0.1% Topical Tacrolimus and Narrow Band Ultraviolet B Monotherapy in Vitiligo Treatment
by: Ameneh Yazdanfar, et al.
Published: (2018-12-01) -
Home phototherapy for patients with vitiligo: challenges and solutions
by: Smith MP, et al.
Published: (2019-06-01) -
Vitiligo: modern methods of therapy
by: Talnikova Е.Е., et al.
Published: (2017-09-01) -
Hyperpigmentation in photo exposed patches of vitiligo following tacrolimus therapy
by: Kanika Sahni, et al.
Published: (2014-01-01) -
Strict Anatomical Colocalization of Vitiligo and Elastolytic Granulomas
by: N. Merino de Paz, et al.
Published: (2010-02-01)